On September 16, 2021, microfluidic cell sorting company NanoCellect Biomedical announced the closing of $35 million in Series C and D financing rounds. The $15 million Series C round was led by Vertical Venture Partners (VVP) and joined by existing investors Agilent, Illumina Ventures, and FusionX Ventures, as well as new investors Yonjin Capital and Sagian Equity. The $20 million Series D round was led by Warburg Pincus, with participation from new investor Casdin Capital, joined by existing investors Illumina Ventures, VVP, Anzu Partners, FusionX Ventures, and Sagian Equity. Wilson Sonsini Goodrich & Rosati advises NanoCellect on IP matters and represented the company in patent matters related to the Series C and D financing rounds.

NanoCellect’s pioneering microfluidic solutions allow researchers to advance cellular discovery by making cell sorting and analysis technology portable, affordable, and easy to use. The company’s current generation WOLF G2 instrument significantly expands the capabilities of gentle benchtop microfluidic cell sorting with two lasers and up to nine colors, making it ideal for use in many different research fields and application areas like single-cell genomics, cell line development, gene editing, antibody discovery, immunology, infectious disease, basic research, and more. The company expects to use the proceeds to further support the WOLF G2 cell sorting system, invest in future product development, and expand the commercial go-to-market for NanoCellect’s high-performance, proprietary microfluidic cell sorting platform.

The Wilson Sonsini team that advised NanoCellect on IP matters related to the transaction was led by partner Vern Norviel and included Peter Amos, and Ellie Han.

For more information, please see NanoCellect’s press release.